Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Insights into the molecular mechanisms underlying the function of lysyl oxidase like 1 in cancers
Xinmeng Wang1,2,3, Xiaoyi Wang1,2,3, Yihan Li4
1Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Dali University, Dali, Yunnan, China.
Abstract:
Cancer is one of the primary causes of human mortality and a significant barrier to increasing human life expectancy. The effective screening, early diagnosis, and treatment of cancer have long been clinical challenges, and thus new biomarkers or molecular targets must be identified to improve the diagnosis and treatment of cancer patients. Lysyl oxidase like 1 (LOXL1), a secreted copper-dependent amine oxidase, is commonly expressed in a variety of cell types. LOXL1 can maintain the steady state of elastin, engage in extracellular matrix (ECM) remodelling. LOXL1 has diverse biological functions, and its dysregulation is the basis of many clinical diseases. The abnormal expression or activation of LOXL1 can disrupt the cellular microenvironment, contributing to the development of various diseases, such as atherosclerosis, tissue damage, fibrosis, and cancer. Recent research has revealed that LOXL1 is often overexpressed in a majority of cancers, where it plays a role in regulating tumor growth and metastasis. However, some studies have also suggested that LOXL1 may have a tumor-suppressive function. Research has indicated that the LOXL1 protein is reduced in human renal cell carcinoma (RCC) and bladder cancer (BLCA), where it acts to suppress tumor growth. Conversely, it is upregulated in human salivary adenoid cystic carcinoma (SACC), non-small cell lung cancer (NSCLC), pleural mesothelioma (PM), brain glioma, prostate cancer (PRAD), gastric cancer (GC), breast cancer (BC), thyroid carcinoma (THCA), pancreatic adenocarcinoma (PAAD), and osteosarcoma (OS). The expression of LOXL1 in colorectal cancer (CRC) remains a topic of debate, as it may either be upregulated or downregulated. These findings imply that LOXL1 may have a dual role in cancer, either inhibiting or facilitating carcinogenesis. This article provides a comprehensive review of the structure and function of LOXL1, along with its associations with cancer. Additionally, it explores the role of LOXL1 in tumor microenvironment remodeling, tumorigenesis, metastasis, and the molecular mechanisms that underpin these processes.
More Related Videos
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Epigenetic Regulation
X-chromosome...